Innovate UK

StimOxyGen is a biotechnology company focused on developing innovative, pH-responsive nanoparticles. These nanoparticles are designed to generate oxygen in hypoxic (low oxygen) tumors, enhancing the effectiveness of cancer treatments like radiotherapy and chemotherapy. The company's core technology involves a nanoparticle formulation that dissolves in the low pH environment of tumors, transiently producing oxygen and thereby maximizing the therapeutic effects of radiotherapy.

LinkGevity is a biotechnology company specializing in drug discovery, with a focus on longevity and age-related diseases. It operates an AI-powered platform designed to expedite the development of life-saving medications. By combining AI and pharmaceutical expertise, the company analyzes extensive datasets to predict and identify promising drug candidates, aiming to extend healthy lifespan and bring innovative treatments to market more swiftly.

Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.

Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Epitopea is a transatlantic biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a novel class of tumor-specific antigens. The company utilizes a proprietary technique that integrates immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's genetic material. This approach, developed through research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal, aims to create therapies that selectively eliminate malignant cells while preserving healthy tissue. By targeting antigens that are broadly shared among patients with the same cancer type, Epitopea seeks to enhance treatment efficacy while minimizing side effects and providing durable benefits.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Lentitek is a cell and gene therapy company focused on developing innovative treatments for cancer patients. The company is dedicated to making advanced therapeutics more accessible by enhancing the production of lentiviral vectors, which are essential for gene therapies. Lentitek employs a proprietary method that utilizes a novel promoter and a triple transfection production process to significantly increase viral yields by tenfold or more. This approach not only improves the efficiency of lentiviral production but also aims to lower production costs for healthcare providers, thereby broadening the availability of its therapies to a larger patient population.

Mestag Therapeutics is a biotechnology company focused on developing innovative therapies for cancer and inflammatory diseases through its unique fibroblast technology. The company leverages emerging insights into the role of activated fibroblast populations in disease progression to create therapeutics that disrupt fibroblast-mediated effects on immune cells. By targeting these mechanisms, Mestag aims to enhance treatment options and improve outcomes for patients suffering from rare and life-threatening conditions.

Naitive is a population health company focused on transforming patient care through the development of AI-enabled clinical pathways. It specializes in creating medical device technology aimed at preventing chronic diseases. The company's software leverages artificial intelligence, clinical data, and digital interventions to enhance the detection, treatment, and management of chronic conditions. By utilizing scalable computational capabilities, Naitive's solutions enable clinicians to improve care coordination while reducing costs, time, and the likelihood of treatment failures.

SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, particularly targeting TUBB4a Leukodystrophy. By addressing the root causes of these conditions, SynaptixBio aims to provide potential curative treatments that could significantly disrupt existing treatment practices. The company is dedicated to translating groundbreaking research into transformative therapeutic options, specifically by altering the expression of a mutated gene responsible for the disease. Through its efforts, SynaptixBio seeks to deliver lifesaving solutions to those affected by this acute subset of leukodystrophies.

BoobyBiome is a company focused on enhancing infant health through the development of probiotic supplements specifically designed for babies with compromised microbiomes. By leveraging specialized expertise and research, BoobyBiome aims to recreate the beneficial bacteria associated with breast milk, particularly for infants born prematurely or those who rely on formula feeding. Their products are formulated to closely mimic the properties of breast milk, providing essential support for gut health and immune system development in infants. Through these innovative probiotic solutions, BoobyBiome seeks to promote healthy growth and development during a critical stage of life.

Awen Oncology is a pre-clinical stage pharmaceutical company focused on developing novel cancer therapies. It specializes in targeting 'developmentally-silent oncogenic drivers', which are genes that contribute to cancer growth but are not typically targeted by existing treatments. The company's approach combines expertise in cell and molecular biology with advanced structural biology and in-silico drug screening to rapidly and efficiently identify and develop effective cancer treatments.

Cumulus Neuroscience develops an AI-based digital biomarker platform to aid in the resolution of the most pressing healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience's platform is intended to provide the critical data and insight required for more rapid, robust, and cost-effective clinical trials that improve patient access to new therapies. The platform's novel insights change the future of clinical trials in brain disorders, allowing life-changing therapies to reach patients faster and more affordably.

BiVictriX Therapeutics Ltd. is a drug discovery and development company based in Alderley Edge, United Kingdom, focused on creating bispecific antibody drug conjugates to address unmet medical needs in blood cancer. Established in 2016, the company leverages its proprietary Bi-Cygni technology to develop innovative therapies for various types of cancers, including Acute Myeloid Leukaemia. BiVictriX specializes in oncology and haematological malignancies, offering a range of services that encompass biotherapeutics, immunotherapy, antibody research, and drug development. The company aims to advance its pharmaceutical products through rigorous development processes to improve treatment outcomes for patients with serious medical conditions.

Nuclera is a biotechnology company specializing in an automated protein prototyping system aimed at enhancing drug discovery processes. Its eProtein Discovery system enables researchers to rapidly produce and test high-quality, soluble, and active proteins, significantly accelerating protein projects. By integrating technology such as cell-free protein synthesis and digital microfluidics, Nuclera provides a high-throughput platform for automated protein access. This innovative approach allows scientists to obtain reliable proteins within a short timeframe, facilitating faster progress in their research and contributing to more efficient drug development efforts.

LIfT BioSciences is a biotechnology company based in London, established in 2016, that specializes in advanced innate immuno-cell therapies. It has developed a unique platform known as Neutrophil Only Leukocyte Infusion Therapy (N-LIfT), which enables the production of Immunomodulatory Alpha Neutrophils (IMANs) from induced pluripotent stem cells (iPSCs). This technology aims to address the limitations of existing therapies for solid tumors by utilizing CAR neutrophil cell therapy. The IMANs can alter the tumor microenvironment, enhancing the immune response and enabling a more effective attack on tumors. By leveraging proprietary enhancement media and genetic engineering, LIfT BioSciences seeks to significantly increase the cancer-fighting capabilities of these cells, offering patients the potential for improved outcomes and lasting immunity against cancer.

Monument Therapeutics is a biotechnology company focused on developing innovative drugs for serious diseases affecting the central nervous system. The company employs proprietary digital biomarkers to reduce variability in patient populations and identify individuals with similar underlying neurobiology. This targeted approach aims to enhance the research and development of neuroscience drugs in areas with significant unmet medical needs, ultimately advancing treatment options for these complex conditions.

Cumulus Neuroscience develops an AI-based digital biomarker platform to aid in the resolution of the most pressing healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience's platform is intended to provide the critical data and insight required for more rapid, robust, and cost-effective clinical trials that improve patient access to new therapies. The platform's novel insights change the future of clinical trials in brain disorders, allowing life-changing therapies to reach patients faster and more affordably.

Presymptom Health is a medical technology company dedicated to advancing healthcare through the development of pre-symptomatic diagnostic tests and clinical decision support algorithms. The company focuses on creating innovative blood tests designed to detect illnesses at an early stage, particularly aiming to predict the onset of sepsis up to three days before symptoms manifest. By enabling earlier intervention, Presymptom Health seeks to improve critical care outcomes and enhance patient management, ultimately contributing to better survival rates and healthcare efficiency.

IXICO plc, established in 1995 and headquartered in London, specializes in providing data analytics services to the global biopharmaceutical industry. The company focuses on the collection, analysis, management, and reporting of data generated during clinical studies, with a particular emphasis on neurological diseases. IXICO's key technologies include Assessa, a digital platform for clinical decision support, and TrialTracker, a comprehensive imaging service workflow management system. The company's end-to-end imaging services are primarily applied in the fields of Alzheimer's, Parkinson's, Huntington's, multiple sclerosis, cerebrovascular, and progressive supranuclear palsy diseases. IXICO's services are utilized to select patients for clinical trials, assess drug safety and efficacy, and for post-marketing surveillance. The company works with pharmaceutical companies, biotech firms, academia, and medical charities worldwide.

Neobe Therapeutics provides immunotherapies, clinical trials, research, and tumor-colonizing bacteria engineering services.

Aelius Biotech specializes in developing advanced models of the mucosal surfaces of the human body, including the gastrointestinal tract and airways. The company is actively working on creating model systems for the eye and cervico-vaginal tract. Aelius Biotech provides a comprehensive range of in vitro and in vivo testing services, including simple lab assays, routine testing, and rheology. Their integrated model gut system allows healthcare industry participants to simulate key processes such as digestion, mucus permeation, and epithelial absorption in one cohesive platform. By conducting human trials and offering detailed insights, Aelius Biotech aids healthcare companies in making informed, data-driven decisions to enhance and de-risk the development of orally delivered products.

SökerData is a biotechnology company that specializes in research and data analysis solutions focused on disease-related datasets. The company has developed a data visualization platform designed to analyze biomarkers in clinical outcomes across various demographics. This platform provides researchers with essential features and tools for interpreting large datasets, facilitating early drug discovery. By enabling researchers to better understand the impact of biomarkers on different populations, SökerData supports informed decision-making and enhances the comprehension of disease outcomes in diverse demographic groups.

PulmoBioMed is a company focused on providing innovative solutions for clinicians and researchers through non-invasive sampling of fluids. The firm has developed a passive fluid aerosol sampler designed to capture exhaled breath condensate and aerosol samples. This product effectively segregates exhaled and environmental particles by size, addressing critical challenges such as sample contamination and loss. PulmoBioMed's technology aims to generate highly reproducible data with precise digital molecular analysis, facilitating the study of biological agents and supporting metabolomic profiling. Through its advancements, the company seeks to enhance research capabilities and improve patient outcomes in the field of respiratory health.

Lucida Medical is a healthcare technology company focused on developing artificial intelligence solutions to enhance the detection and diagnosis of cancer. The company’s flagship product, Pi, is a CE marked medical device that utilizes multiparametric and diffusion MRI to support prostate cancer diagnosis. By leveraging advanced imaging and multi-omics biomarkers, Lucida Medical aims to provide clinicians with accurate, accessible, and cost-effective tools for cancer screening and management. Their innovative technology is designed to improve the efficiency of cancer detection, ultimately enabling healthcare professionals to make timely and informed decisions regarding patient care.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, particularly targeting TUBB4a Leukodystrophy. By addressing the root causes of these conditions, SynaptixBio aims to provide potential curative treatments that could significantly disrupt existing treatment practices. The company is dedicated to translating groundbreaking research into transformative therapeutic options, specifically by altering the expression of a mutated gene responsible for the disease. Through its efforts, SynaptixBio seeks to deliver lifesaving solutions to those affected by this acute subset of leukodystrophies.

Physiomics Plc is a consulting firm based in Oxford, United Kingdom, specializing in services for pharmaceutical companies in the realms of quantitative pharmacology and computational biology. Established in 2001, the company utilizes its proprietary Virtual Tumour predictive software to offer modeling, simulation, and data analysis services, primarily focused on oncology research and development. By combining systems biology with advanced mathematical techniques, Physiomics aims to optimize dosing and scheduling of oncology drugs during pre-clinical and clinical trials, enhancing the efficacy of drug combinations and streamlining the overall drug development process. The company's operations extend across the United Kingdom, the European Union, Switzerland, and the United States, with a commitment to advancing personalized medicine through innovative technology.

Stablepharma Ltd is a biotechnology company based in Bath, United Kingdom, focused on developing innovative processes for vaccine stabilization. Its technology platform, StablevaX™, transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration, addressing significant challenges in cold chain logistics. By enabling pre-dosed and stable vaccine delivery, Stablepharma aims to eliminate waste and reduce costs in the distribution of medical products. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates actively with global vaccine manufacturers, academic institutions, and non-governmental organizations to advance its pipeline of thermostable solutions. Established in 2012, Stablepharma is dedicated to improving access to vaccines for children and adults, while also contributing to reduced carbon dioxide emissions in the healthcare sector.

AstronauTx is a biotechnology company focused on developing innovative treatments for Alzheimer's disease and other neurodegenerative conditions. The company specializes in restoring the normal function of astrocytes, which are crucial for supporting neuronal activity and maintaining brain health. In healthy individuals, astrocytes play a vital role in metabolism and the integrity of the blood-brain barrier; however, in neurodegenerative diseases, their dysfunction can contribute to neurotoxicity. By targeting these processes, AstronauTx aims to enable healthcare professionals to more effectively address the challenges posed by dementias, ultimately improving patient outcomes.

ZiO Health is a biotechnology company focused on enhancing patient outcomes through its innovative pocket-sized laboratory testing technology. The company has developed proprietary biosensor devices that utilize machine learning algorithms to provide real-time results tailored to individual patient profiles. These multi-functional electronic devices are designed for measuring, testing, and detecting the molecular composition of various chemical and biological substances, enabling users to assess the presence, absence, or quantity of specific target molecules. By delivering quality home diagnostics and personalized testing solutions, ZiO Health aims to empower individuals to optimize their health and prevent illness.

Ramanomics extracts microorganisms and their antimicrobial profiles from clinical specimens.

Peptimatrix is a biotechnology company specializing in the development of an innovative, animal-free 3D cell culture platform. Utilizing a peptide hydrogel technology, the company aims to reduce and replace the use of animals and animal-derived products in drug development and research. By combining expertise from matrix biologists, cancer scientists, toxicologists, and biomaterial engineers, Peptimatrix offers a more reproducible, reliable, and ethical alternative to traditional cell culture methods. The company's mission is to provide researchers with a better way to model development and disease.

Kalium Health Ltd is a medical technology company based in Cambridge, United Kingdom, that specializes in designing and manufacturing innovative tests for blood potassium concentration. Founded in 2018 and previously known as Kalium Diagnostics Ltd, the company focuses on patient-centric approaches to manage kidney disease, which significantly impacts healthcare costs. Kalium Health is developing a user-friendly finger-prick blood test that allows patients to monitor their potassium levels conveniently and affordably, addressing a critical risk associated with kidney disease. This technology aims to provide real-time, clinically actionable health insights into cardiorenal diseases, thereby transforming the standard of care for millions of patients. With a clear regulatory pathway and a targeted go-to-market strategy, Kalium Health is positioned to make a significant impact in the field of kidney care.

genedrive plc is a commercial stage medical devices company, targeting opportunities in infectious diseases, biosurveillance, and animal applications. Our Genedrive® system is positioned to offer lower cost, easy to use, point of need or clinic-based molecular diagnostic tests via a 'razor/razor blade'​ business model across an increasing range of applications. Genedrive® is rapidly reconfigurable for specific assays and is suitable for use outside a traditional hospital setting. The system analyses nucleic acids from fresh or stored samples to provide rapid diagnosis and decision making.

Autolomous Ltd is a technology company founded in 2019 and based in Mayfair, United Kingdom, that specializes in developing software solutions for cell and gene therapy manufacturers. Its flagship platform, autoloMATE®, is a cloud-native system that offers comprehensive, end-to-end solutions for advanced therapy manufacturing. The platform facilitates the scheduling of patient cell collections, transportation logistics, and tracking of the manufacturing process to ensure compliance with regulatory requirements. Additionally, autoloMATE® supports the management of electronic batch records, provides insights reporting, and oversees review and release activities. The software is designed to be highly configurable, allowing clients to customize workflows to suit their needs. Autolomous emphasizes compliance with regulatory standards and has achieved multiple ISO certifications in areas such as information security, quality management, and environmental management. By leveraging advanced technology and secure data management practices, Autolomous aims to enhance the availability and affordability of autologous medicines for patients.

CGT Catapult is a UK-based centre of excellence dedicated to advancing the cell and gene therapy sector globally. Supported by Innovate UK, it aims to facilitate the translation of early-stage research into commercially viable therapies. Based in central London with over 120 experts and state-of-the-art laboratories, CGT Catapult offers a comprehensive platform for product development, clinical trials, manufacturing, regulatory support, health economics, and market access expertise. Additionally, they are constructing a £55 million large-scale GMP manufacturing centre to accelerate the delivery of cell and gene therapies to patients worldwide.

Neu Health is a developer of a smartphone-based clinical platform designed to enhance personalized care for patients with Parkinson's disease and dementia. The company's innovative platform leverages artificial intelligence to monitor and interpret digital measures of clinically relevant symptoms. By optimizing condition management, Neu Health aims to reduce the burden on clinicians while improving patient outcomes. This approach enables healthcare providers and caregivers to deliver more efficient and effective care, addressing the challenges associated with managing these complex neurological conditions.

Lindus Health is a clinical research organization that specializes in managing end-to-end clinical trials for healthcare and biotechnology companies. The company offers services such as ethics and IRB submissions, trial monitoring, data management, biostatistics, regulatory affairs, and payor relations. Lindus Health employs an in-house team of clinicians and researchers to accelerate the clinical trial process using its proprietary software platform, Curebase OS, which automates workflows and reduces manual inefficiencies. The company also leverages real-world patient data for precise participant recruitment and smarter trial design, aiming to make clinical trials faster and more cost-effective while improving patient treatment outcomes.

QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to enhance life expectancy for patients suffering from glioblastoma, a brain tumor known for its poor prognosis and limited treatment options. Recognizing the significant gaps in effective therapies, co-founder Dr. Richard Fu, an academic neurosurgeon, teamed up with biomedical engineer Dr. Chris Bullock to address design flaws in existing electric field therapies. Their solution leverages advanced materials science, including the use of graphene, to optimize device performance and patient outcomes. Since its inception, QV Bioelectronics has garnered nearly $1 million in funding from various UK institutions and over $1 million from international life science investors. The company operates from its research hub in Alderley Park, Cheshire, and boasts a multidisciplinary team with extensive experience in bringing innovative medical devices to the clinic.

GenoME Diagnostics is a biotechnology company focused on developing innovative blood tests aimed at improving cancer detection and diagnosis. The company has created the OvaME product, which enhances the traditional CA125 blood tests, offering a more accurate and earlier detection of various cancers. By employing advanced techniques, GenoME Diagnostics aims to minimize misdiagnosis and late detection, enabling healthcare professionals to diagnose and treat patients more effectively. This commitment to developing life-saving diagnostic tools positions the company as a significant player in the field of oncology diagnostics.

Myma Medical is a bright, cutting-edge start-up with a model to greatly improve the experiences of people who are having fertility issues.

Fallouh Healthcare specializes in the development and manufacturing of medical devices and AI-based software for cardiac surgery. Their products aim to enhance patient safety and streamline surgical workflows. Key offerings include systems for monitoring and protecting the heart during surgery, and AI-driven tools to detect and prevent complications like tamponade.

Brainstem is a DePIN to collect and utilise wearable health data. Our mission is to revolutionize healthcare and improve lives through remote screening, ongoing monitoring, digital treatment alternatives, and tools to share data with practitioners, researchers, and others. We are committed to building a network of users who are willing to share their data and embracing collaboration with smart minds to speed innovation. With our vision of being a 24/7 virtual health assistant specializing in sleep, mental, cardio, and neuro health, we are at the forefront of digital health.

52 North Health is a medical technology company focused on enhancing healthcare outcomes for cancer patients. It specializes in an AI-driven, portable finger prick blood test that measures neutrophil count and C-reactive protein (CRP) levels at home. This enables early detection of neutropenic sepsis risk during chemotherapy, improving patient safety and quality of life. The device facilitates timely management of the condition, offering a reliable and cost-effective solution for both patients and healthcare providers.

The Medicines Discovery Catapult is the centre of national expertise for the discovery of medicines.

LabGenius Ltd is a biopharmaceutical company based in London, United Kingdom, focused on discovering and developing new protein therapeutics to address unmet medical needs, including conditions like Inflammatory Bowel Disease. Founded in 2012, the company utilizes a machine learning-driven evolution engine and a robotic platform known as EVA, which is capable of designing, conducting, and learning from its own experiments. This innovative approach integrates advanced technologies from synthetic biology, robotics, and machine learning, enabling the engineering of protein drugs with enhanced properties such as protease stability and tissue penetration. By leveraging these cutting-edge methodologies, LabGenius aims to provide physicians with access to novel protein therapeutics that are developed through automation and intelligent design.

ProtonDx is a diagnostic platform that specializes in molecular testing services, focusing on the rapid and precise detection of multiple pathogens from samples. The company develops point-of-care diagnostic test devices aimed at assisting healthcare professionals in diagnosing infectious diseases. Utilizing innovative microchip technology, ProtonDx integrates molecular biology with machine learning, allowing for swift deployment in clinical settings. This enables healthcare organizations to efficiently manage infected patients and monitor pandemic situations in real-time. ProtonDx emphasizes speed, sensitivity, specificity, and convenience in its offerings, positioning itself as a vital resource for frontline healthcare staff.

aTen Therapeutics is a biotechnology company focused on developing innovative therapeutic antibodies aimed at treating major diseases, particularly cancer. The company employs novel antibody approaches to target crucial control pathways that play a significant role in cancer cell growth, invasion, and metastasis. By utilizing anti-cancer agents, aTen Therapeutics' products have the potential to inhibit cancer cell proliferation and improve treatment outcomes for patients. Their commitment to advancing biopharmaceutical solutions reflects a goal of enhancing the quality of life for individuals affected by cancer and preventing the progression of the disease. With a management team experienced in the biopharmaceutical industry, aTen Therapeutics is well-positioned to contribute to the development of effective therapies that can significantly impact patient care.

BoobyBiome is a company focused on enhancing infant health through the development of probiotic supplements specifically designed for babies with compromised microbiomes. By leveraging specialized expertise and research, BoobyBiome aims to recreate the beneficial bacteria associated with breast milk, particularly for infants born prematurely or those who rely on formula feeding. Their products are formulated to closely mimic the properties of breast milk, providing essential support for gut health and immune system development in infants. Through these innovative probiotic solutions, BoobyBiome seeks to promote healthy growth and development during a critical stage of life.

BoobyBiome is a company focused on enhancing infant health through the development of probiotic supplements specifically designed for babies with compromised microbiomes. By leveraging specialized expertise and research, BoobyBiome aims to recreate the beneficial bacteria associated with breast milk, particularly for infants born prematurely or those who rely on formula feeding. Their products are formulated to closely mimic the properties of breast milk, providing essential support for gut health and immune system development in infants. Through these innovative probiotic solutions, BoobyBiome seeks to promote healthy growth and development during a critical stage of life.

Awakn Life Sciences is a clinical-stage biotechnology company dedicated to developing and delivering innovative psychedelic medicine aimed at treating addiction, with a primary focus on Alcohol Use Disorder (AUD). The company comprises a multidisciplinary team of chemists, scientists, psychiatrists, and psychologists who are working to create the next generation of psychedelic drugs and therapies, as well as the technologies that enable their use. Recognizing the inadequacies of current treatment options for AUD, Awakn aims to provide breakthrough therapeutics for individuals suffering from addiction, addressing a significant medical need both in the United States and internationally.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

NRG Therapeutics is a drug discovery company established in 2018, specializing in therapeutic solutions aimed at restoring mitochondrial function to address neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, and motor neuron disease. Founded by a team of professionals with extensive experience in the biotech and pharmaceutical sectors, the company focuses on developing brain-penetrant mitochondrial permeability transition pore inhibitors specifically for Parkinson's disease. NRG Therapeutics seeks to create innovative medicines that preserve mitochondrial function, thereby enabling effective treatment options for patients suffering from chronic neurodegenerative disorders.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

BoobyBiome is a company focused on enhancing infant health through the development of probiotic supplements specifically designed for babies with compromised microbiomes. By leveraging specialized expertise and research, BoobyBiome aims to recreate the beneficial bacteria associated with breast milk, particularly for infants born prematurely or those who rely on formula feeding. Their products are formulated to closely mimic the properties of breast milk, providing essential support for gut health and immune system development in infants. Through these innovative probiotic solutions, BoobyBiome seeks to promote healthy growth and development during a critical stage of life.

Medwise.ai operates a customizable search platform designed to enhance clinical decision support for doctors. Leveraging natural language processing and artificial intelligence, the platform allows healthcare professionals to efficiently search for and organize medical knowledge. By utilizing real-world data, Medwise.ai provides valuable insights and intelligence to various stakeholders within the healthcare ecosystem. This innovative approach not only extends the capabilities of physicians but also aims to improve patient care and outcomes.

GenoME Diagnostics is a biotechnology company focused on developing innovative blood tests aimed at improving cancer detection and diagnosis. The company has created the OvaME product, which enhances the traditional CA125 blood tests, offering a more accurate and earlier detection of various cancers. By employing advanced techniques, GenoME Diagnostics aims to minimize misdiagnosis and late detection, enabling healthcare professionals to diagnose and treat patients more effectively. This commitment to developing life-saving diagnostic tools positions the company as a significant player in the field of oncology diagnostics.

Cytochroma manufacture genetically diverse stem cell-derived models to predict the safety and effect of drugs in a global population. Cytochroma’s automated cell manufacture, physiologically relevant models and rapid screening platform makes preclinical testing faster, safer and smarter.

Oxford Heartbeat is a developer of medical device software focused on improving the planning and execution of cardiovascular surgeries. The company offers a healthcare platform that provides surgeons with critical insights into real patient blood vessels, enabling them to visualize interactions between medical devices and arterial walls, as well as navigate through tissues and bones. This advanced simulation technology allows for unprecedented visibility during keyhole surgeries, facilitating rehearsal of surgical procedures and the selection of optimal approaches tailored to individual patients. By leveraging predictive computations, big data, and artificial intelligence, Oxford Heartbeat aims to enhance surgical preparation, ultimately leading to reduced complication rates, lower associated costs, and improved patient care. The company is actively conducting prospective clinical trials in NHS hospitals, supported by the UK government's AI in Health and Care Awards.

AgPlus Diagnostics Ltd. is a UK-based company specializing in the development of diagnostic platform technology aimed at providing quantitative point-of-care (PoC) testing solutions for various clinical applications, including both human and veterinary diagnostics. Founded in 2009 and headquartered in Sharnbrook, the company designs, manufactures, and supplies diagnostic tests and associated readers. AgPlus Diagnostics focuses on creating portable diagnostic devices that utilize electrochemical signaling and measurement systems, enabling healthcare providers to deliver personalized care through rapid and accurate testing. This innovative approach facilitates timely diagnostic results, allowing healthcare professionals to make critical treatment decisions quickly, ultimately benefiting patient outcomes.

CryoLogyx is an early-stage biotechnology company focused on developing innovative cryopreservation technology that enhances the freezing, storage, and transportation of cells. By utilizing advanced cryoprotectants, CryoLogyx ensures that cells remain viable and ready for use in drug discovery, diagnostics, and cell therapy applications. The company's proprietary technology facilitates the delivery of frozen, ready-to-use cells, allowing healthcare researchers to access and utilize these vital resources in their preferred formats, thereby transforming the landscape of cell storage and transportation.

Camallergy Limited is a biopharmaceutical company based in Cambridge, United Kingdom, founded in 2015. The company specializes in developing and manufacturing oral immunotherapy drugs, particularly targeting food allergies, with a focus on peanut allergies. Camallergy's lead product offers a novel treatment designed to provide "bite-proof" protection to patients within 14 weeks of therapy. This innovative approach is grounded in unique intellectual property and clinical research initiated at Cambridge University Hospitals NHS Foundation Trust. By aiming to deliver patient-centric solutions, Camallergy seeks to improve the quality of life for individuals suffering from food allergies, allowing them to live without the constant fear of allergic reactions.

CN Bio Innovations Ltd, established in 2008 and headquartered in Cambridge, UK, specializes in developing and providing Organ-on-Chip devices to pharmaceutical and biotech companies. These devices enable more accurate preclinical drug testing by replicating the physiological functions of human organs. CN Bio's offerings include microphysiological systems and consumables, used by various industries to analyze novel compounds, assess toxicity and safety, and support research scientists in investigating biological processes. The company's flagship product, the LiverChip platform, features a full viral lifecycle model of hepatitis B, currently employed in drug discovery collaborations with leading pharma and biotech firms. CN Bio, part of Hong Kong-based CN Innovations Holdings Limited, works closely with academic experts and is backed by prestigious grants, aiming to accelerate the development of transformative therapies worldwide.

IgniteData is a company focused on transforming clinical trials through innovative technology solutions. Its flagship product, Archer, is a cloud-based virtual research assistant that facilitates secure transmission of clinical data from electronic health records to electronic data capture systems. By automating patient data processes, IgniteData aims to enhance the efficiency of clinical research, enabling researchers to collect trial data more swiftly. This approach not only accelerates the development of crucial therapies but also improves the quality of studies while reducing the workload for research teams. Ultimately, IgniteData is dedicated to streamlining key clinical research processes to ensure that important medical advancements reach patients more quickly.

4D Medicine specializes in creating innovative solutions for the targeted and controlled regeneration of human tissue through the development of degradable, implantable medical devices. Utilizing novel photopolymer materials, the company is advancing a range of products that are currently undergoing regulatory clearance with the Food and Drug Administration. These resorbable medical devices aim to enhance patient outcomes in various applications, including musculoskeletal surgery, soft tissue repair, and drug delivery. By focusing on regulatory approval and effective medical applications, 4D Medicine seeks to provide valuable options for medical device suppliers and healthcare providers.

NovaBiotics Ltd. is a clinical-stage biotechnology company based in Aberdeen, United Kingdom, with a location in Raleigh, North Carolina. Founded in 2004, the company specializes in the design, development, and manufacture of innovative anti-infective drugs aimed at treating medically unmet diseases. Its product portfolio includes Novexatin, a cationic antifungal peptide targeting fungal nail infections; Lynovex, an oral and inhaled therapy for cystic fibrosis-related lung conditions; Novamycin, an antifungal peptide for various invasive fungal infections; and Novarifyn, an antibacterial peptide for bacterial infections. NovaBiotics is committed to advancing its proprietary antimicrobial peptide platform, which is pivotal in creating new antifungal and antibacterial agents. The company's robust pipeline addresses challenging therapeutic needs, particularly in the realm of difficult-to-treat infections caused by emerging drug-resistant pathogens.

BioFab is developing innovative new products for healthcare diagnostics with a particular focus on point-of-care testing (POCT) applications. Our vision is to create a truly universal diagnostic platform that can bring the clinical lab to the patient. Our innovative approach will enable this vision by offering a diverse range of test cartridges which can run on a single, universal reader device. It will not need any user training and will simply require the addition of the patient sample. Fully automated processing will then take place in a totally enclosed cartridge and will then deliver laboratory grade results without risk of cross-contamination. We are developing a test for Covid-19 with the support of an Innovate UK Smart award and will expand the product range to cover cardio-vascular disease, respiratory/gastric infections, blood infections (sepsis), STDs, Cancer and other conditions. We also have the ability to access the rapidly expanding Chinese market and have route-to-market and manufacturing base via established partners in China.

AgPlus Diagnostics Ltd. is a UK-based company specializing in the development of diagnostic platform technology aimed at providing quantitative point-of-care (PoC) testing solutions for various clinical applications, including both human and veterinary diagnostics. Founded in 2009 and headquartered in Sharnbrook, the company designs, manufactures, and supplies diagnostic tests and associated readers. AgPlus Diagnostics focuses on creating portable diagnostic devices that utilize electrochemical signaling and measurement systems, enabling healthcare providers to deliver personalized care through rapid and accurate testing. This innovative approach facilitates timely diagnostic results, allowing healthcare professionals to make critical treatment decisions quickly, ultimately benefiting patient outcomes.

Ablatus Therapeutics Limited is a medical device company based in Norwich, United Kingdom, focused on developing and commercializing innovative tissue ablation technology for the treatment of challenging and often inoperable solid cancer tumors. Founded in 2015, the company has created a proprietary Bimodal Electric Tissue Ablation system that utilizes radiofrequency (RF) energy to generate localized heating and effectively destroy target tissues. This advanced approach provides clinicians with new options for treating tumors, aiming to improve patient outcomes in oncology care.

Reflection Therapeutics is developing cell therapy technology against neuroinflammation across the board.

Albus Health is a startup originating from the University of Oxford, focusing on the development of an intelligent nocturnal monitoring platform for personalized home health monitoring. The platform enables passive, contactless, and objective tracking of various symptoms and environmental metrics. This innovative system is designed primarily for use in clinical trials by leading pharmaceutical companies, facilitating the monitoring of nocturnal symptoms and aiding in the prediction of respiratory emergencies. By providing detailed insights into patient conditions, Albus Health's technology supports pharmaceutical firms in optimizing their clinical studies while enhancing revenue potential.

QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to enhance life expectancy for patients suffering from glioblastoma, a brain tumor known for its poor prognosis and limited treatment options. Recognizing the significant gaps in effective therapies, co-founder Dr. Richard Fu, an academic neurosurgeon, teamed up with biomedical engineer Dr. Chris Bullock to address design flaws in existing electric field therapies. Their solution leverages advanced materials science, including the use of graphene, to optimize device performance and patient outcomes. Since its inception, QV Bioelectronics has garnered nearly $1 million in funding from various UK institutions and over $1 million from international life science investors. The company operates from its research hub in Alderley Park, Cheshire, and boasts a multidisciplinary team with extensive experience in bringing innovative medical devices to the clinic.

Medwise.ai operates a customizable search platform designed to enhance clinical decision support for doctors. Leveraging natural language processing and artificial intelligence, the platform allows healthcare professionals to efficiently search for and organize medical knowledge. By utilizing real-world data, Medwise.ai provides valuable insights and intelligence to various stakeholders within the healthcare ecosystem. This innovative approach not only extends the capabilities of physicians but also aims to improve patient care and outcomes.

ONKO is a provider of unified cancer care. ONKO combines digital technology with the support of healthcare professionals to provide patients with personalised expertise from cancer dietitians, physiotherapists, specialist nurses and psychologists.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing innovative technology for assessing seizure susceptibility. The company has created a novel platform that focuses on diagnosing and prognosticating neurological conditions, specifically targeting epilepsy. Utilizing a patented seizure risk score derived from routine electroencephalogram (EEG) recordings, Neuronostics' technology aims to facilitate early diagnosis and prognosis of epilepsy. This advancement is designed to empower clinicians to enhance patient care and improve the quality of life for individuals living with this neurological condition.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing innovative technology for assessing seizure susceptibility. The company has created a novel platform that focuses on diagnosing and prognosticating neurological conditions, specifically targeting epilepsy. Utilizing a patented seizure risk score derived from routine electroencephalogram (EEG) recordings, Neuronostics' technology aims to facilitate early diagnosis and prognosis of epilepsy. This advancement is designed to empower clinicians to enhance patient care and improve the quality of life for individuals living with this neurological condition.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, that specializes in developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, addressing the needs of over 300 million patients worldwide affected by osteoarthritis. The company's flagship product, FibroFix, is a hydrogel implant designed to emulate human knee cartilage, enabling effective repair and regeneration of damaged tissues. Orthox offers several variations of FibroFix, including FibroFix Meniscus for meniscal cartilage repair and FibroFix Cartilage for articular cartilage damage. The implants promote integration with the body's cells, facilitating a return to active, pain-free living. With plans to expand its technology to other joints and additional applications beyond orthopaedics, Orthox is positioned to capitalize on the rapidly growing biomaterials market, projected to exceed $250 billion by 2025.

Symbiosis Pharmaceutical Services Limited is a contract manufacturer specializing in sterile pharmaceuticals for clinical trials, established in 2011 in Stirling, United Kingdom. The company addresses the growing global demand for niche sterile manufacturing by providing filling and finishing services tailored to the needs of biotech and specialty pharmaceutical companies. Its purpose-built facility is designed to accommodate both biologic and small molecule production, focusing on small-scale injectable products. Symbiosis distinguishes itself by offering rapid access to manufacturing slots and quick release of drug products, enabling clients to meet tight timelines effectively. With a commitment to maintaining regulatory compliance, Symbiosis supports its clients in navigating the complexities of drug product development and supply.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

LUNAC Therapeutics is a biotechnology company focused on the development of advanced oral anticoagulant drugs aimed at treating and preventing life-threatening thrombotic events. The company's innovative drug formulations are designed to minimize bleeding risks in patients, allowing healthcare providers to manage high-risk patients with safe dose escalation. By addressing critical needs in anticoagulation therapy, LUNAC Therapeutics seeks to improve patient outcomes and enhance treatment options in the healthcare landscape.

Sense Biodetection Limited is a molecular diagnostics company based in Abingdon, United Kingdom, established in 2013. The company specializes in developing user-centered, handheld diagnostic tests aimed at enhancing healthcare decisions and processes, particularly in the areas of infections and oncology. Its flagship product, True Point-of-Care, utilizes advanced molecular methods, including polymerase chain reaction (PCR), to deliver rapid and accurate results. This capability allows clinics and medical professionals to detect infections swiftly and make informed treatment decisions in a decentralized healthcare setting, ultimately improving patient outcomes.

BrainWaveBank, established in 2015, is a UK-based brain health research company. It specializes in developing data-centric solutions to track and understand cognitive health. The company's flagship product, also named BrainWaveBank, is a wearable EEG headset that measures brain activity while users engage in mobile games, enabling daily tracking of cognitive health at home. This data is securely stored and analyzed, creating neurocognitive profiles for individuals and populations, and aiding clinical professionals in advancing brain health research and treatments. The company has offices in Belfast, Northern Ireland, and Dublin, Ireland.

Px HealthCare is a company focused on enhancing patient experiences to achieve better oncology outcomes. It has developed the OWise platform, which consists of evidence-based mobile and web applications tailored for individuals living with breast and prostate cancer. OWise promotes value-based cancer care by providing personalized digital tools that allow patients to share health data in real time with their healthcare teams. The platform addresses the financial and individual burdens of cancer, aiming to improve patients' well-being and clinical outcomes while also reducing healthcare costs. The OWise app has been recognized for its effectiveness, with high recommendations from both patients and clinicians. Px HealthCare leverages advanced data analytics to analyze anonymized, real-world patient-reported outcome data, generating insights that can enhance treatment effectiveness and cost-efficiency. Overall, OWise serves as a key patient-driven support platform, integrating improved patient experience, clinical outcomes, and economic viability in cancer care.

Healum is a developer of AI-powered software and applications aimed at enhancing self-management for individuals with long-term health conditions. The company’s technology enables users to effectively monitor and comprehend their physical and mental well-being. By leveraging data-driven insights and evidence-based behavioral interventions, Healum provides personalized care and support tailored to each patient's needs. This approach not only empowers patients in managing their chronic conditions but also aids healthcare professionals in delivering more effective care. Through its innovative solutions, Healum strives to improve health outcomes and promote greater patient engagement in their health management.

Albus Health is a startup originating from the University of Oxford, focusing on the development of an intelligent nocturnal monitoring platform for personalized home health monitoring. The platform enables passive, contactless, and objective tracking of various symptoms and environmental metrics. This innovative system is designed primarily for use in clinical trials by leading pharmaceutical companies, facilitating the monitoring of nocturnal symptoms and aiding in the prediction of respiratory emergencies. By providing detailed insights into patient conditions, Albus Health's technology supports pharmaceutical firms in optimizing their clinical studies while enhancing revenue potential.

CGT Catapult is a UK-based centre of excellence dedicated to advancing the cell and gene therapy sector globally. Supported by Innovate UK, it aims to facilitate the translation of early-stage research into commercially viable therapies. Based in central London with over 120 experts and state-of-the-art laboratories, CGT Catapult offers a comprehensive platform for product development, clinical trials, manufacturing, regulatory support, health economics, and market access expertise. Additionally, they are constructing a £55 million large-scale GMP manufacturing centre to accelerate the delivery of cell and gene therapies to patients worldwide.

Freeline Therapeutics, established in 2015 and based in Stevenage, UK, is a clinical-stage biotechnology company specializing in the development of systemic adeno-associated virus (AAV) vector-mediated gene therapies. The company focuses on treating inherited, debilitating diseases by delivering functional copies of therapeutic genes into human liver cells, enabling the production of functional proteins in the bloodstream. Freeline's pipeline includes FLT180a for hemophilia B, FLT190 for Fabry disease, and FLT201 for Gaucher disease Type 1, all in various stages of clinical trials. Additionally, the company offers expertise in CMC process development, analytics, and AAV technologies.

Symbiosis Pharmaceutical Services Limited is a contract manufacturer specializing in sterile pharmaceuticals for clinical trials, established in 2011 in Stirling, United Kingdom. The company addresses the growing global demand for niche sterile manufacturing by providing filling and finishing services tailored to the needs of biotech and specialty pharmaceutical companies. Its purpose-built facility is designed to accommodate both biologic and small molecule production, focusing on small-scale injectable products. Symbiosis distinguishes itself by offering rapid access to manufacturing slots and quick release of drug products, enabling clients to meet tight timelines effectively. With a commitment to maintaining regulatory compliance, Symbiosis supports its clients in navigating the complexities of drug product development and supply.

Nanna Therapeutics Limited, established in 2012 and headquartered in Cambridge, UK, is a biotechnology company focused on developing drugs for age-related diseases such as mitochondrial, neurodegenerative, cardiovascular/metabolic, joint/tissue diseases, and cancer. As of April 2020, the company operates as a subsidiary of Astellas Pharma Europe Ltd. Nanna Therapeutics employs a unique approach by targeting fundamental cellular processes to create innovative treatments for these conditions, with a particular emphasis on mitochondria, the energy source in every cell. The company's proprietary drug discovery platform, TIME (Totally Integrated Medicines Engine), combines advanced technologies like microfluidics and artificial intelligence to accelerate drug development and disrupt traditional methods of creating new medicines.

Concentric Health is a company focused on transforming health decision-making through its innovative e-consent application. The application enhances efficiency by addressing backlog issues and minimizing medico-legal risks through the use of trusted content. It aims to simplify complex processes for both patients and clinicians, fostering shared decision-making that is informed by patient outcomes. By providing a secure and auditable platform, Concentric Health improves the overall experience for users, ultimately leading to better health outcomes.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

A UK pharmaceutical development company, AKL Research & Development Ltd (AKLRD) is committed to transforming patient’s lives through innovative solutions that meet unmet needs.AKLRD is developing novel therapeutics for inflammatory diseases with a high unmet need, including osteoarthritis, Alzheimer’s, rheumatoid arthritis & scleroderma, a rare connective tissue disease.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

MediSieve Ltd. is a London-based medical device company specializing in Magnetic Blood Filtration (MBF) technology aimed at treating blood-borne diseases. Founded in 2014, the company has developed a system that utilizes a magnetic filter to physically remove infected blood cells from a patient's bloodstream. The process involves circulating blood through an external loop where targeted magnetic particles are infused, binding to disease-relevant targets. This filtered blood then passes through a magnetic filter that captures the particles and bound targets, allowing the unaffected blood to return to the patient without the particles entering their body. MediSieve's innovative approach is applicable to various conditions, including malaria, leukaemia, sepsis, and other blood-borne diseases, enhancing the efficacy and safety of existing therapies. The company operates out of the Imperial Incubator in White City, London, where it conducts product development and validation in its dedicated laboratory facilities.

PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. Established in 2017, the company offers PredictSURE IBD, a diagnostic tool designed to identify patients with Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, who are at risk of severe, relapsing disease. This simple lab test requires only a small blood sample and provides critical insights that enable healthcare providers to tailor early biologic therapies for at-risk patients. By delivering personalized treatment options, PredictImmune aims to improve disease management and clinical outcomes for individuals suffering from IBD, addressing an important need recognized by physicians, patients, and payors alike.

PepGen Ltd. is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the next generation of nucleic acid therapeutics, particularly in the treatment of severe neuromuscular and neurologic diseases. Incorporated in 2018, PepGen has developed its Enhanced Delivery Oligonucleotide (EDO) platform, which is designed to improve the uptake and activity of conjugated oligonucleotide therapeutics. The company's innovative EDO peptides enhance tissue penetration, cellular uptake, and nuclear delivery, demonstrating their ability to transport oligonucleotides effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. PepGen aims to unlock the clinical potential of these transformative therapeutics, with a particular emphasis on the effective delivery of antisense oligonucleotides, and is advancing its novel conjugate therapeutics toward clinical application.

RoslinCT is a UK-based Contract Development and Manufacturing Organisation (CDMO) that specializes in cell and gene therapy. The company offers a range of services tailored for organizations developing cell-based therapeutic products. Its expertise encompasses tissue procurement, cryopreservation studies, pre-clinical studies, and analytical development. By providing these services, RoslinCT enables its clients to create compliant, sustainable, and cost-effective therapies, supporting advancements in the field of regenerative medicine.

Medherant Limited is a clinical-stage company based in Coventry, United Kingdom, focused on developing innovative treatments for pain and central nervous system diseases through advanced transdermal drug delivery technology. Founded in 2014 by Professor David Haddleton and the University of Warwick, the company has created the TEPI Patch, a novel transdermal system that utilizes a unique adhesive designed to improve drug loading capacity and enhance delivery efficiency. This technology addresses limitations found in current patch systems, which often struggle with drug loading, as well as issues associated with creams and gels, such as inadequate dose control. Medherant aims to provide patients with effective medication delivery solutions that minimize complications linked to traditional oral administration.